Dendritic cell CD83: A therapeutic target or innocent bystander?

Immunology Letters

Volumn 115, Issue 1, 2008, Pages 1-8

  Prazma, Charlene M ^a   Tedder, Thomas F ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CD83; CD83 ligand; Dendritic cell

Indexed keywords

AMINO ACID; CD83 ANTIGEN; IMMUNOGLOBULIN; MEMBRANE ANTIGEN; RECOMBINANT PROTEIN;

ANTIGEN FUNCTION; B LYMPHOCYTE; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; DENDRITIC CELL; IMMUNE SYSTEM; IMMUNOTHERAPY; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE ACTIVATION; THERAPY EFFECT;

ANIMALS; ANTIGEN-PRESENTING CELLS; ANTIGENS, CD; DENDRITIC CELLS; HUMANS; IMMUNOGLOBULINS; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; T-LYMPHOCYTES;

EID: 37349076271     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.imlet.2007.10.001     Document Type: Review

References (48)

1. Zhou L.-J., Schwarting R., Smith H.M., and Tedder T.F. A novel cell-surface molecule expressed by human interdigitating reticulum cells. Langerhans cells and activated lymphocytes is a new member of the immunoglobulin superfamily. J Immunol 149 (1992) 735-742
2. Fujimoto Y., and Tedder T.F. CD83: a regulatory molecule of the immune system with great potential for therapeutic application. J Med Dent Sci 53 (2006) 85-91
3. Pashine A, Göpfert U, Chen J, Hoffmann E, Dietrich PS, Peng SL. Failed efficacy of soluble human CD83-Ig in allogeneic mixed lymphocyte reactions and experimental autoimmune encephalomyelitis: implications for a lack of therapeutic potential. Immunol Lett 2007, doi:10.1016/j.imlet.2007.08.011.
4. Dudziak D., Nimmerjahn F., Bornkamm G.W., and Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol 174 (2005) 6672-6676
5. Lechmann M., Krooshoop D.J.E.B., Dudziak D., Kremmer E., Kuhnt C., Figdor C.G., et al. The extracellular domain of CD83 inhibits dendritic cell-mediated T cell stimulation and binds to a ligand on dendritic cells. J Exp Med 194 (2001) 1813-1821
6. Scholler N., Hayden-Ledbetter M., Dahlin A., Hellstrom I., Hellstrom K.E., and Ledbetter J.A. Cutting edge: CD83 regulates the development of cellular immunity. J Immunol 168 (2002) 2599-2602
7. + T cells. J Immunol 166 (2001) 3865-3872
8. Xu J.F., Huang B.J., Yin H., Xiong P., Feng W., Xu Y., et al. A limited course of soluble CD83 delays acute cellular rejection of MHC-mismatched mouse skin allografts. Transplant Int 20 (2007) 266-276
9. Yang S., Yang Y., Raycraft J., Zhang H., Kanan S., Guo Y., et al. Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137. Proc Natl Acad Sci USA 101 (2004) 4990-4995
10. Zinser E., Lechmann M., Golka A., Hock B., and Steinkasserer A. Determination of the inhibitory activity and biological half-live of soluble CD83: comparison of wild type and mutant isoforms. Immunobiology 211 (2006) 449-453
11. Zinser E., Lechmann M., Golka A., Lutz M.B., and Steinkasserer A. Prevention and treatment of experimental autoimmune encephalomyelitis by soluble CD83. J Exp Med 200 (2004) 345-351
12. Zhou L.-J., and Tedder T.F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol 154 (1995) 3821-3835
13. + blood dendritic cells. Blood 86 (1995) 3295-3301
14. + T cell longevity in vivo. J Immunol 179 (2007) 4550-4562
15. + dendritic cells. Proc Natl Acad Sci USA 93 (1996) 2588-2592
16. Sieling P.A., Jullien D., Dahlem M., Tedder T.F., Rea T.H., Modlin R.L., et al. CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. J Immunol 162 (1999) 1851-1858
17. Kozlow E.J., Wilson G.L., Fox C.H., and Kehrl J.H. Subtractive cDNA cloning of a novel member of the Ig gene superfamily expressed at high levels in activated B lymphocytes. Blood 81 (1993) 454-461
18. McKinsey T., Chu Z.-L., Tedder T.F., and Ballard D.W. Transcription factor NF-kB regulates inducible CD83 gene expression in activated T lymphocytes. Mol Immunol 37 (2000) 783-788
19. Aerts-Toegaert C., Heirman C., Tuyaerts S., Corthals J., Aerts J.L., Bonehill A., et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol 37 (2007) 686-695
20. Sorg U.R., Morse T.M., Patton W.N., Hock B.D., Angus H.B., Robinson B.A., et al. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology 29 (1997) 294-299
21. Dudziak D., Kieser A., Dirmeier U., Nimmerjahn F., Berchtold S., Steinkasserer A., et al. Latent membrane protein 1 of Epstein-Barr virus induces CD83 by the NF-κB signaling pathway. J Virol 77 (2003) 8290-8298
22. + T cell development in the thymus. Cell 108 (2002) 755-767
23. + T cells. J Immunol 173 (2004) 2995-3001
24. Wolenski M., Cramer S.O., Ehrlich S., Steeg C., Grossschupff G., Tenner-Racz K., et al. Expression of CD83 in the murine immune system. Med Microbiol Immunol 192 (2003) 189-192
25. Cramer S.O., Trumpfheller C., Mehlhoop U., Moré S., Fleischer B., and von Bonin A. Activation-induced expression of murine CD83 on T cells and identification of a specific CD83 ligand on murine B cells. Int Immunol 12 (2000) 1347-1351
26. Breloer M., Kretschmer B., Luthje K., Ehrlich S., Ritter U., Bickert T., et al. CD83 is a regulator of murine B cell function in vivo. Eur J Immunol 37 (2007) 634-648
27. Kretschmer B., Luthje K., Guse A.H., Ehrlich S., Koch-Nolte F., Haag F., et al. CD83 modulates B cell function in vitro: increased IL-10 and reduced Ig secretion by CD83Tg B cells. PLoS ONE 2 (2007) e755
28. Berchtold S., Mühl-Zürbes P., Heufler C., Winklehner P., Schuler G., and Steinkasserer A. Cloning, recombinant expression and biochemical characterization of the murine CD83 molecule which is specifically upregulated during dendritic cell maturation. FEBS Lett 461 (1999) 211-216
29. Cao W., Lee S.H., and Lu J. CD83 is preformed inside monocytes, macrophages and dendritic cells, but it is only stably expressed on activated dendritic cells. Biochem J 385 (2005) 85-93
30. Klein E., Koch S., Borm B., Neumann J., Herzog V., Koch N., et al. CD83 localization in a recycling compartment of immature human monocyte-derived dendritic cells. Int Immunol 17 (2005) 477-487
31. Lechmann M., Kremmer E., Sticht H., and Steinkasserer A. Overexpression, purification, and biochemical characterization of the extracellular human CD83 domain and generation of monoclonal antibodies. Protein Expr Purif 24 (2002) 445-452
32. Hock B.D., Kato M., McKenzie J.L., and Hart D.N. A soluble form of CD83 is released from activated dendritic cells and B lymphocytes, and is detectable in normal human sera. Int Immunol 13 (2001) 959-967
33. Twist C.J., Beier D.R., Disteche M.C., Edelhoff S., and Tedder T.F. The mouse CD83 antigen: structure, domain organization and chromosome localization. Immunogenetics 48 (1998) 383-393
34. Lechmann M., Kotzor N., Zinser E., Prechtel A.T., Sticht H., and Steinkasserer A. CD83 is a dimer: comparative analysis of monomeric and dimeric isoforms. Biochem Biophys Res Commun 329 (2005) 132-139
35. Ohta Y., Landis E., Boulay T., Phillips R.B., Collet B., Secombes C.J., et al. Homologs of CD83 from elasmobranch and teleost fish. J Immunol 173 (2004) 4553-4560
36. + T cells and preferential enrichment for antigen specificity. Blood 107 (2006) 1528-1536
37. Kotzor N., Lechmann M., Zinser E., and Steinkasserer A. The soluble form of CD83 dramatically changes the cytoskeleton of dendritic cells. Immunobiology 209 (2004) 129-140
38. Kuwano Y., Prazma C.M., Yazawa N., Watanabe R., Ishiura N., Kumanogoh A., et al. CD83 influences cell-surface MHC class II expression on B cells and other antigen-presenting cells. Int Immunol 19 (2007) 977-992
39. Luthje K., Cramer S.O., Ehrlich S., Veit A., Steeg C., Fleischer B., et al. Transgenic expression of a CD83-immunoglobulin fusion protein impairs the development of immune-competent CD4-positive T cells. Eur J Immunol 36 (2006) 2035-2045
40. Lundell A.C., Adlerberth I., Lindberg E., Karlsson H., Ekberg S., Aberg N., et al. Increased levels of circulating soluble CD14 but not CD83 in infants are associated with early intestinal colonization with Staphylococcus aureus. Clin Exp Allergy 37 (2007) 62-71
41. Hock B.D., O'Donnell J.L., Taylor K., Steinkasserer A., McKenzie J.L., Rothwell A.G., et al. Levels of the soluble forms of CD80, CD86, and CD83 are elevated in the synovial fluid of rheumatoid arthritis patients. Tissue Antigens 67 (2006) 57-60
42. Hock B.D., Haring L.F., Steinkasserer A., Taylor K.G., Patton W.N., and McKenzie J.L. The soluble form of CD83 is present at elevated levels in a number of hematological malignancies. Leuk Res 28 (2004) 237-241
43. Senechal B., Boruchov A.M., Reagan J.L., Hart D.N., and Young J.W. Infection of mature monocyte-derived dendritic cells with human cytomegalovirus inhibits stimulation of T-cell proliferation via the release of soluble CD83. Blood 103 (2004) 4207-4215
44. Tedder T.F. Cell surface receptor shedding: a means of regulating function. Am J Respir Cell Mol Biol 5 (1991) 305-306
45. Schleiffenbaum B.E., Spertini O., and Tedder T.F. Soluble l-selectin is present in human plasma at high levels and retains functional activity. J Cell Biol 119 (1992) 229-238
46. Tu L., Poe J.C., Kadono T., Venturi G.M., Bullard D.C., Tedder T.F., and Steeber D.A. A functional role for circulating mouse l-selectin in regulating leukocyte/endothelial cell interactions in vivo. J Immunol 169 (2002) 2034-2043
47. Prechtel A.T., Turza N.M., Theodoridis A.A., and Steinkasserer A. CD83 knockdown in monocyte-derived dendritic cells by small interfering RNA leads to a diminished T cell stimulation. J Immunol 178 (2007) 5454-5464
48. Ma-Krupa W., Jeon M.S., Spoerl S., Tedder T.F., Goronzy J.J., and Weyand C.M. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 199 (2004) 173-183